Abstract
Blethen and Chaslow (JCEM 57:1031, 1983), recently reported that the ratio of GH by Tandem Hybritech monoclonal immunoradiometric assay (Tandem) to standard polyclonal radioimmunoassay (RIA), might predict the outcome of GH therapeutic trials.
We studied the effect of GH therapy on 16 patients whose height was <3rd percentile and bone age delayed ≥2 SD. Each patient had a normal GH response (≥10 ng/ml) to insulin arginine stimulation (assayed by RIA). GH was also assayed by Tandem. Seven patients increased their pretreatment growth rate by >2 cm/yr (R). Nine patients did not respond to GH (NR).
There was no significant difference between the Tandem/RIA ratio of R and NR patients. The ratio did not predict the response to GH therapy.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chalew, S., Raiti, S. & Kowarski, A. THE RATIO OF GROWTH HORMONE (GH) BY TANDEM MONOCLONAL ASSAY/POLYCLONAL RIA DOES NOT PREDICT RESPONSE TO GH THERAPY. Pediatr Res 18 (Suppl 4), 165 (1984). https://doi.org/10.1203/00006450-198404001-00434
Issue Date:
DOI: https://doi.org/10.1203/00006450-198404001-00434
- Springer Nature America, Inc.